Insmed Incorporated (NASDAQ:INSM) Shares Sold by Algert Global LLC

Algert Global LLC reduced its position in Insmed Incorporated (NASDAQ:INSM) by 7.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 75,754 shares of the biopharmaceutical company’s stock after selling 5,747 shares during the quarter. Algert Global LLC’s holdings in Insmed were worth $5,230,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in INSM. Vanguard Group Inc. grew its position in shares of Insmed by 6.3% in the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company’s stock valued at $1,257,838,000 after purchasing an additional 1,075,796 shares in the last quarter. Darwin Global Management Ltd. grew its holdings in Insmed by 23.5% in the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock valued at $894,796,000 after buying an additional 2,463,261 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Insmed by 1.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company’s stock valued at $877,113,000 after buying an additional 123,429 shares in the last quarter. Capital International Investors increased its stake in shares of Insmed by 9.1% in the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company’s stock worth $491,357,000 after acquiring an additional 593,206 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Insmed by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock worth $282,243,000 after acquiring an additional 273,759 shares during the period.

Insmed Stock Up 0.4 %

Shares of NASDAQ INSM opened at $72.58 on Tuesday. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91. The stock has a market cap of $13.20 billion, a P/E ratio of -12.98 and a beta of 0.84. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The business’s fifty day simple moving average is $73.31 and its 200-day simple moving average is $73.44.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. As a group, equities analysts predict that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In other news, CFO Sara Bonstein sold 18,322 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total value of $1,471,439.82. Following the completion of the transaction, the chief financial officer now owns 118,863 shares in the company, valued at approximately $9,545,887.53. This represents a 13.36 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO William Lewis sold 6,830 shares of Insmed stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $70.16, for a total transaction of $479,192.80. Following the sale, the chief executive officer now owns 233,924 shares in the company, valued at $16,412,107.84. This represents a 2.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 368,737 shares of company stock valued at $29,364,317. Insiders own 3.00% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on INSM shares. Wells Fargo & Company raised their price objective on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Bank of America increased their price target on Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a report on Thursday, March 20th. Guggenheim restated a “buy” rating and issued a $101.00 price objective on shares of Insmed in a report on Tuesday, February 25th. Morgan Stanley lifted their price target on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $100.00 price target on shares of Insmed in a research note on Wednesday, March 19th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $94.00.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.